These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 9340582)

  • 21. Efficacy and tolerability of moclobemide compared with fluvoxamine in depressive disorder (DSM III). A French/Swiss double-blind trial.
    Bougerol T; Uchida C; Gachoud JP; Köhler M; Mikkelsen H
    Psychopharmacology (Berl); 1992; 106 Suppl():S102-8. PubMed ID: 1546121
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Treatment with selective and reversible monoamine oxidase inhibitors in depressed patients: is there a biological effect proportional to the dose?].
    Radat F; Berlin I; Varoquaux O; Ferreri M; Puech A
    Ann Med Psychol (Paris); 1996 Jun; 154(3):204-6. PubMed ID: 8766502
    [No Abstract]   [Full Text] [Related]  

  • 23. Moclobemide versus fluoxetine for a major depressive episode.
    Reynaert C; Parent M; Mirel J; Janne P; Haazen L
    Psychopharmacology (Berl); 1995 Mar; 118(2):183-7. PubMed ID: 7617806
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
    Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Prognostic value of pharmaco-EEG in depression treated with moclobemide].
    Wiśniewski G; Jakitowicz J; Nowicki Z; Pankiewicz P
    Psychiatr Pol; 2002; 36(6 Suppl):93-8. PubMed ID: 12647427
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Incidence and therapeutic relevance of the adverse effects of antidepressive agents within the scope of ambulatory neurologic treatment].
    Schmidt LG; Schüssler G; Linden M; Müller-Oerlinghausen B
    Fortschr Neurol Psychiatr; 1988 Apr; 56(4):111-8. PubMed ID: 3384381
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparison of the efficacy and tolerability of moclobemide given as a single daily dose or in three divided doses per day for the treatment of patients with a major depressive episode (DSM-III-R).
    Newburn G; Edwards R; Thomas H; Collier J; Fox K; Collins C; Cramer D; Reeves J; Caracatsanis A
    J Clin Psychopharmacol; 1995 Aug; 15(4 Suppl 2):10S-15S. PubMed ID: 7593724
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Depression in medical illness. Workshop report.
    Paykel E
    Int Clin Psychopharmacol; 1993 Jan; 7(3-4):205-7. PubMed ID: 8468445
    [No Abstract]   [Full Text] [Related]  

  • 29. A comparison of moclobemide and imipramine in treatment of depression.
    Casacchia M; Rossi A
    Pharmacopsychiatry; 1989 Jul; 22(4):152-5. PubMed ID: 2668979
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unaltered monocyte function in patients with major depression before and after three months of antidepressive therapy.
    Landmann R; Schaub B; Link S; Wacker HR
    Biol Psychiatry; 1997 Mar; 41(6):675-81. PubMed ID: 9066991
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Moclobemide versus fluoxetine for major depressive episodes.
    Geerts S; Bruynooghe F; De Cuyper H; Demeulemeester F; Haazen L
    Clin Neuropharmacol; 1994; 17 Suppl 1():S50-7. PubMed ID: 7954484
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical picture and treatment of subsequent depressive episodes--results of Polish multicenter study].
    Rybakowski J; Kiejna A; Nawacka-Pawlaczyk D; Kargul M
    Psychiatr Pol; 2003; 37(3):419-31. PubMed ID: 13677972
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Moclobemide in treatment of somatoform depression. A case report].
    Rütten J
    Fortschr Med; 1994 Mar; 112(7):95-6. PubMed ID: 8175100
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Orthostatic side effects of clomipramine and moclobemide during treatment for depression.
    Stage KB;
    Nord J Psychiatry; 2005; 59(4):298-301. PubMed ID: 16195134
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term tolerability and effectiveness of duloxetine in the treatment of major depressive disorder.
    Dunner DL; Wilson M; Fava M; Kornstein S; Munoz R; O'Reardon J; Trivedi M; Wohlreich M
    Depress Anxiety; 2008; 25(5):E1-8. PubMed ID: 17621644
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictors of an acute antidepressant response to fluoxetine and sertraline.
    Flament MF; Lane RM; Zhu R; Ying Z
    Int Clin Psychopharmacol; 1999 Sep; 14(5):259-75. PubMed ID: 10529069
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Affective and anxiety comorbidity in post-traumatic stress disorder treatment trials of sertraline.
    Brady KT; Clary CM
    Compr Psychiatry; 2003; 44(5):360-9. PubMed ID: 14505296
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The comparative efficacy of Aurorix and amitriptyline in treating depressions].
    Iakovlev VA
    Voen Med Zh; 1997 Apr; 318(4):37-8. PubMed ID: 9221592
    [No Abstract]   [Full Text] [Related]  

  • 40. [Special aspects of antidepressive therapy].
    Nervenarzt; 1994 Mar; 65(3 Suppl [speziell]):1-8. PubMed ID: 9218059
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.